10 Dec 2009
Chancellor Alistair Darling has announced a reduction in the corporation tax on royalty income from 28% to 10%.
The move could potentially save pharmaceutical giants such as GlaxoSmithKline "billions of pounds", according to Kevin Hindley, a managing director at international tax advisers A&M Taxand.
The "patent box" changes announced in the PBR 09 will enable royalty payments made to companies for their intellectual property to pay the lower rate from 2013. The move provides a "huge incentive" for companies to stay in the UK rather than move its operations overseas, said Hindley.
In the pre-Budget report papers it is predicted the move will cost the government £1.3bn in lost revenue. However, Hindley predicts the reduced rate would boost UK business.
The Treasury's estimate is based on royalty income of £7.2bn in 2013. Yet many companies might change their plans to move to more favourable tax regimes due to the new rate, Hindley believes. "They could also attract companies to register their intellectual property in the UK and in that sense it could be a lot less costly [to the Treasury]," said Hindley.
The move is competitive, as it sits between the rates in Luxembourg set at 6% and Ireland at 12%.
However, other advisers bemoaned the delay in implementing the new rate.
Sue Bonney, head of tax for KPMG Europe, said: "It's a positive move but you could get that kind of relief in the Netherlands tomorrow."
She added that although the move was a step in the right direction, it needed to be made much "quicker" to help the UK's competitiveness.
IN OUR VIEW
This could give the UK a competitive edge – but why not straight away? Will companies hang around or move to, for example, Luxembourg where the rate is much lower. The Netherlands also allows many types of royalty payments to be taxed at 6%. The UK government needs to instigate this move quicker – and with a broader brush – to show it’s really IP-friendly.
You may also like
Careers
Search for jobs
Click to search our database of all the latest accountancy roles
Create a profile
Click to set up your profile and let the best recruiters find you
Jobs by email
Sign up to receive regular updates with the latest roles suitable for you
Briefings
By looking at the reasons supplier statements became unfashionable, and the reasons why it is different today, this paper delves into the many benefits that can be obtained by automating the process.
Having a real and true view of your organisation’s current financial position, and having the right systems and processes in place, will ensure that you can make strong choices and are ready to capitalise on opportunities
Visitor comments Add your comment
so much for fairness
Darling made great play of "fairness" in the PBR so I'm confused why "pharmaceutical giants such as GlaxoSmithKline" are being singled out for highly favourable treatment.
Furthermore patents and IP are something of a hot topic in some circles, questioning the societal benefits vs. cost (a complicated, in-depth debate that I'll not pretend to be able to cover in a short comment).
Fundamentally however consider why a company that obtains a patent should be taxed lower than one that chooses not to. The latter retains all of the societal benefit of the former but without any of the societal costs.
(I'll caveat that I've not seen the detail on this yet)
Posted by: Dave, 10 Dec 2009 | 00:00